COPD
Conference Coverage
Benefits of BGF triple fixed-dose therapy consistent in COPD patients without exacerbation history
NEW ORLEANS – Findings were similar to overall results of KRONOS, suggesting exacerbation history did not drive...
Conference Coverage
Tiotropium/olodaterol improved lung function in steroid-free patients with COPD
NEW ORLEANS – Outcomes with the combination therapy compared well with tiotropium monotherapy in patients not receiving inhaled corticosteroids
Conference Coverage
Readmission for COPD exacerbation upped in-hospital mortality risk
NEW ORLEANS – Reduction of readmission rates has potential to improve health and economic outcomes, according to researchers.
From the Journals
Opioids, benzodiazepines carry greater risk of COPD-related hospitalization
The risk of hospitalization because of respiratory events for patients with COPD was especially high when opioid and benzodiazepine medications...
Conference Coverage
Recent COPD exacerbation did not affect aclidinium’s efficacy in high-risk patients
NEW ORLEANS – A history of recent exacerbations didn’t significantly affect the safety or efficacy of aclidinium bromide in patients with moderate...
Conference Coverage
Beta-blocker treatment did not reduce exacerbation risk in COPD
The use of metoprolol did not significantly reduce the median time to first exacerbation in COPD, compared with placebo.
From the Journals
Influenza vaccination modestly reduces risk of hospitalizations in patients with COPD
Older patients with COPD need more effective influenza vaccines and other preventive strategies.
From the Journals
New guideline conditionally recommends long-term home NIV for COPD patients
To provide insight into the clinical application of long-term home NIV, the European Respiratory Society convened a task force of 20 clinicians,...
Feature
Wildfire smoke has acute cardiorespiratory impact, but long-term effects still under study
While research advances, the unforgiving wildfire season looms, assuring more destruction of property and threats to cardiorespiratory health.
From the Journals
Benralizumab trials cast doubt on eosinophil depletion’s role in COPD treatment
The anti–interleukin-5 receptor antibody did not reduce COPD exacerbations in phase 3 trials.